# Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection

> **NCT01157598** · PHASE3 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 56 (estimated)

## Conditions studied

- Gastric Adenoma
- Gastric Cancer

## Interventions

- **DEVICE:** bispectral index monitoring

## Key facts

- **NCT ID:** NCT01157598
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2010-09
- **Final completion:** —
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2010-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157598, "Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01157598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*